Coronavirus vaccines have demonstrated just how key collaborations are. Should we be doing more, and what makes them effective?
FACILITATED BY
JAMES FRY | Partner and Head of Life Sciences | Mills & Reeve
PANELLISTS INCLUDE
MATTHEW DURDY | Chief Executive Officer | Cell and Gene Therapy Catapult JENNY LAIRD | Vice President, Search & Evaluation Pain & Neurodegeneration | Eli Lilly MATTHEW DUCHARS | Chief Executive Officer | VMIC UK ROISIN NICAMHLAOIBH | Head of Partnerships and Business Development | Rosalind Franklin Institute
Cytiva’s Global Biopharma Resilience Index - based on a survey of more than 1,000 senior biopharma executives - takes a holistic look at the industry across five key pillars at a time when its health is vital. Fresh data shows there is work to be done to secure its future.
Emmanuel will speak about the challenges in the industry and what we can do to meet them.
EMMANUEL LIGNER | President and Chief Executive Officer | Cytiva
What requirements do Biotech companies need to consider during clinical development to ensure that patients will gain access to their innovative therapies? How must Biotech companies adapt in order to be successful in an increasingly cost-conscious world?
FACILITATED BY
MEL WALKERÂ | Managing Director | BioPharma Futures
PANELLISTS INCLUDE
DOUG DANISON | Head of Europe | Bluebird Bio CAROLE LONGSON | Independent Senior Adviser, Life Science Policy, HTA and Market Access | Vice Chair | Medicines Discovery Catapult TIM HAINES | Chairman and Managing Partner | Abingworth LLP WILLS HUGHES-WILSON | Chief Patient Access & Commercial Planning | Mereo Biopharma
What does it take to raise seed funding, and what do you need to demonstrate for angels/investors to part with their money?
FACILITATED BY
JONATHAN APPLEBYÂ | Chief Scientific Officer | Cell and Gene Therapy Catapult (CGT Catapult)
PANELLISTS INCLUDE
AJAY MISTRYÂ | Founder and Chief Executive Officer | OPPILOTECH JAMES ZHANGÂ | Co-Founder and Chief Executive Officer | Phoenix DX CLARE TERLOUW | Head of Ventures | LifeArc GRAHAM BOND | Managing Partner | RSM NATALIA NOVAC Â | Senior Director, Emerging Technology & Innovation, Corporate Business Development | Eli Lilly HANNAH WADE Â | Head of Investor Partnerships | CPI
How, where, when and if to grow are decisions critical to the success of all biotech focused companies – spanning products to services. How do you plan, implement and adapt your growth strategy?
Value creation through growth is an imperative for all companies. What strategies work best in the biotech world?
Strategies invariably evolve over time. We will hear from companies that have pivoted from service to product - and vice versa. Is this by design or by necessity?
Self-proclaimed serial entrepreneurs are abundant. Where are the serial scalers? Do they exist? Are they hidden? Are they tied up in longer-term projects?
What tools and techniques exist to support the development of growth strategies? What works? Are they transferable?
PETER LYFORD | Business Development Director | Porton Pharma Solutions VICKY STEADMAN | Senior Director, Business Development | Sai Life Sciences NATHALIE HUTHER | Senior Director of Business Development, Europe | Arcinova, a Quotient Sciences business STEPHEN TOOKER | Vice President, Commercial Packaging – Europe | PCI Pharma Services RICHARD WEAVER | Senior Vice President – Pre-clinical Development | Sygnature Discovery HELEN BARKER | Head of Pharmaceutical Development | Reneo Pharma
Should our products be patient-focused from the start, or should we be more mindful of milestones at the outset?
FACILITATED BY
JESÚS ZURDO | Global Head Cell, Gene Therapy & Bioproduction | Horizon Discovery
PANELLISTS INCLUDE
PAT FURLONG | Founding President & Chief Executive Officer | Parent Project Muscular Dystrophy MIKE FRODSHAMÂ | Chief Technical Officer | QuayPharma ALEX HAMILTON | Partner | Syncona Investment Management STEVE McCONCHIE| Chief Executive Officer | Aptus Clinical TIM LUKER | Vice President Emerging Technology and Innovation| Eli Lilly CHRISTIAN JONES | Chief Commercial Officer | Nanoform
Raising investment and meeting milestones is difficult enough in normal times. We hear from those who have thrived through the pandemic.
FACILITATED BY
ZAHID MONEERÂ | Head of Healthcare, Investment Banking Division | BNP Paribas
PANELLISTS INCLUDE
JOLYON MARTIN | Founder and Business Development | PetMedix EDDIE BLAIR | Chairman | Virokine Therapeutics JASON MELLAD | Chief Executive Officer | Start Codon DAVID ATKINS | Chief Executive Officer | Congenica DAVID BEADLE | Non-Executive Director | Phico Therapeutics
COVID-19 vaccines have shown the public just how fast we can develop, assess and approve medicines. How can we accelerate these timelines outside of a pandemic?
FACILITATED BY
IAN MUIR | Chief Executive Officer | Porton Biopharma
PANELLISTS INCLUDE
PAUL STOTT | Chief Executive Officer | Seda Pharmaceutical Development Services JILL RECKLESS | Chief Executive Officer | RxCelerate FLIC GABBAY | Managing Partner | tranScrip SANDY DOUGLAS | Research Group Leader | The University of Oxford NICK SMITH | Associate Director of Operations | Cobra Biologics
Brexit and the imminent funding gap has led to companies looking to locate elsewhere. We hear from countries/regions trying to attract Life Science companies.
FACILITATED BY
KATH MACKAY | Managing Director | Bruntwood SciTech – Alderley Park
PANELLISTS INCLUDE
PATRICK DRISCOLL | Chief Financial Officer | CN Bio Innovations WILL BROOKS | Investment Director | Downing ADRIAN HILL | HealthTec Development Manager | UKRI – STFC, Harwell Campus MAYER SCHREIBER | Chief Executive Officer | Discovery Park RORY MAW | Director | The Oxford Science Park
Faced with ongoing change what have we learnt that will serve us well as we lead in 2021 and beyond…
• Why will leading change continue to be important in 2021 and beyond? • How can we reset and reenergize? • What are the key success factors in leading change?
FACILITATED BY
KATHRYN SIMPSON | Business Consultant | Kathryn Simpson Consulting
PANELLISTS INCLUDE
JOHN POTTAGE | Former Senior Vice President, Chief Scientific and Medical Officer | ViiV Healthcare BRUCE CLARK | Past President and Chief Executive Officer | Medicago Inc TOBY REID | Chief Executive Officer | BioCity Group PRIYA MANDE | Chief Operating Officer | PsiOxus Therapeutics JOANNA GOULD | Chief Executive Officer and Co-founder | VisusNano
£1m - £5m is the new funding valley of death. How do you effectively position your business for Series A funds, and how do you select investors that are right for you?
AMIT SHAH | Biotech Venture Capital Investor | S.R. One Ltd CATHERINE PICKERING | Chief Executive Officer and co-founder | iOnctura HAKAN GOKER | Vice President | M Ventures CHARLOTTE CASEBOURNE | Co-Founder & Chief Executive Officer | Theolytic Nanosyrinx | speaker to be confirmed
MAIREADH PEDERSEN | Chief Executive Officer | QuayPharma JASON FOSTER | Chief Executive Officer and Executive Director | Ori Biotech NEIL JONES | Chief Business Officer | Vaccines Manufacturing & Innovation Centre LUCY FOLEY | Director of Biologics| CPI IAN MCKAY | Innovation Lead for Advanced Therapies | InnovateUK
With attention and funding diverting to vaccines in 2020, other disease areas like oncology have been left behind. How can we ensure they catch up?
FACILITATED BY
EMMA PALMER FOSTER | Strategic Communications Consultant | The Oxford Science Park
PANELLISTS INCLUDE
EUAN CAMERON | Chief Executive Officer & Founder | COHESION Medical FRAN CRAWFORD | Chief Executive Officer | Somaserve GREG BROOKE | Senior Lecturer in Molecular and Cellular Biology | University of Essex ANDREW FADDEN | Vice President and Head of Corporate Development | Enara Bio
Vaccine supply has demonstrated the importance of cold chain and agile supply chains. Do we have the infrastructure to supply, and ensure security? How can we build a robust supply chain to ensure medicines delivery doesn’t become rate-limiting?
FACILITATED BY
JOHN VANDORE | Business Development | Harwell Campus
PANELLISTS INCLUDE
JOHN COLEMAN | Head of Quality and Business Development | Your Special Delivery Service SONIA HOUGHTON | Chief Executive Officer & Co-Founder | Cryoniss TOBY PETERS | Professor of Cold Economy | University of Birmingham EDWIN DYSON | Managing Director | Cryo Storage Solutions
With increased public funding in coronavirus detection and vaccines, and restrictions on funding from the EU, will there be a major gap in life science funding?
FACILITATED BY
RICHARD HEBDON | Interim Deputy Director - Health & Life Sciences | Innovate UK
PANELLISTS INCLUDE
CLAIRE BROWNÂ | Investment Director | BioCity PHIL L'HUILLIER | Chief Executive Officer | CatalYm REBECCA TODD | Investment Director | Longwall Venture Partners JOE DE SOUSA | Senior Leader, Non-Exec Director and Independent Consultant | Melhor Consulting DEBORA LUCARELLI | Chief Executive Officer | Enhanc3D Genomics